


December 16, 2021



Volition Executes its First Supply and Licensing Contract for its Nu.Q® Vet Cancer Screening Test in Asia

- SAGE Healthcare Private Limited appointed to serve as a non-exclusive licensee and distributor for Volition's Nu.Q® Vet Cancer Screening Test in centralized labs in Singapore, with launch planned in Singapore in the first quarter of 2022 followed by expansion in conjunction with SAGE Healthcare into centralized labs in other key Asian markets.
- Volition's global strategy is to implement similar agreements with multiple companies to ensure the broadest possible accessibility to the Nu.Q® Test worldwide.
- Volition continues to make significant progress in ongoing negotiations with the multi-national veterinary companies referred to in its prior disclosures, with several term sheets well-progressed and one or more definitive contracts anticipated in the first quarter of 2022, to provide global coverage for the Nu.Q® Test.

AUSTIN, Texas, Dec. 16, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of cancers and other life-altering diseases in both humans and animals, has announced that it has entered into its first contract for the Nu.Q® Vet Cancer Screening Test, a supply and licensing agreement with SAGE Healthcare.



"With the global veterinary market being so fragmented, we determined the best way to ensure our test is accessible worldwide is to have multiple agreements with both large multi-

nationals and regional players," commented Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development, LLC. "I am delighted to announce this agreement for centralized labs in Asia, a large and rapidly expanding pet care market. I expect this will be the first of many agreements, including with the big multi-nationals, so that we can cover the whole world through centralized labs and also with point of care."

<https://youtu.be/sZySltlh53w>

An interview with Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC.

Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition commented "With rapid urbanization and rising disposable income, pets have become an important part of Asian families. Over half of the Asian population have a companion animal, with almost a third of households owning a dog. We believe that the opportunity for the Nu.Q[®] Vet Cancer Screening Test is huge. SAGE Healthcare is one of the strongest and most respected distributors of leading veterinary brands in Singapore. We are pleased to appoint SAGE Healthcare to offer the Nu.Q[®] Vet Cancer Screening Test widely in Singapore and later avail the Nu.Q[®] Vet Cancer Screening Test in other countries in Asia."

"We are delighted to be appointed as a licensee and distributor of the Nu.Q[®] Vet Cancer Screening Test in Singapore and other countries in Asia. Adding the Nu.Q[®] Vet Cancer Screening Test to the routine wellness check-up for older dogs and at-risk breeds could help detect cancer early, when treatment is more effective and affordable. We believe that this is a clear unmet need in the veterinary space," commented Ms. Irene Kum General Manager for SAGE Healthcare Private Limited. "We are excited to launch the test in Singapore in the first quarter of 2022 and with planned subsequent launches in other Asian markets thereafter."

To learn more about Volition Veterinary and Nu.Q[®] Vet please visit our webpage at <https://volition.com/veterinary>

About SAGE

SAGE Healthcare is a leading distributor of premium veterinary products and services in Asia. Founded by distribution veterans of clinical and research products, SAGE provides a full array of distribution services from marketing and sales, supply chain, education, and registration services. SAGE is headquartered in Singapore, with businesses in Malaysia, Thailand, and China.

About Volition

Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an

indication that disease is present. Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Volition's research and development activities are centered in Belgium, with a small laboratory in California and additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic and disease monitoring products to market.

For more information about Volition, visit Volition's website volition.com or connect with us via:

Twitter: <https://twitter.com/volitionrx>

LinkedIn: <https://www.linkedin.com/company/volitionrx>

Facebook: <https://www.facebook.com/VolitionRx/>

YouTube: <https://www.youtube.com/user/VolitionRx>

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

| | |
|---|--|
| Louise Batchelor, Volition mediarelations@volition.com +44 (0)7557 774620 | Scott Powell, Volition investorrelations@volition.com +1 (646) 650 1351 |
| Jen Lewis, Mind&Matter Jen.Lewis@ashfieldhealth.com +44 (0)7809 867943 | Joseph Green, Edison Advisors jgreen@edisongroup.com +1 (646) 653 7030 |

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, the success of negotiations and the timing, completion and execution of term sheets and/or agreements with third parties regarding the licensing and distribution of Volition's products, the effectiveness of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and the timing of product launches and publications. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be

unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

📄 View original content to download multimedia <https://www.prnewswire.com/news-releases/volition-executes-its-first-supply-and-licensing-contract-for-its-nuq-vet-cancer-screening-test-in-asia-301446407.html>

SOURCE VolitionRx Limited